Patients who underwent transcatheter aortic valve replacement (TAVR) with the Evolut R platform had better clinical outcomes compared to patients who underwent TAVR with the CoreValve platform, according to the results of research presented at TCT 2016.

Paul Sorajja, MD, FACC, et al., analyzed acute, in-hospital, and 30-day outcome data from the STS/ACC TVT Registry of patients with native aortic stenosis who underwent TAVR with either the Evolut R or CoreValve platforms. The analysis examined 9,616 patients who underwent TAVR between January 2014 and April 2016.

The results of the analysis showed that, in patients who underwent TAVR with the Evolut R platform, there was a lower acute need for a second prosthesis (2.2 percent vs. 4.5 percent), a lower incidence of moderate or severe paravalvular regurgitation (4.4 percent vs. 6.2 percent) and a shorter length of hospital stay (4 vs. 5 days), compared to those treated with the CoreValve. Further, at 30-day follow-up, patients treated with the Evolut R platform had lower incidences of all-cause mortality and the need for a permanent pacemaker.

The authors conclude that “commercial adoption of TAVR with Evolut R is associated with significant clinical improvements in the acute procedural outcomes for patients undergoing TAVR for aortic stenosis.” 

Keywords: Transcatheter Cardiovascular Therapeutics, Aortic Valve Stenosis, Incidence, Length of Stay, Prostheses and Implants, Registries, Transcatheter Aortic Valve Replacement, STS/ACC TVT Registry

< Back to Listings